IQVIA Holdings Inc. (IQV)
IQV trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/0001628280-26-008322-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IQV on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001478242 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.3B |
| Net income | $1.4B |
| Operating income | $2.2B |
| Net margin | 8.3% |
| Operating margin | 13.4% |
| Revenue growth | +5.9% |
| Cash | $2.0B |
| Total assets | $29.9B |
| P/E (computed) | 32.1× |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $2.2B cash; operating cash flow $684.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 164,800,000 (2026-10-20); 170,300,000 a year earlier; 182,500,000 three years earlier. | Cover page 2026-10-20 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $51.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.4B | $350.0M | $825.0M | $2.2B | $16.1B | $17.3B | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | $4.4B | $256.0M | $558.0M | $1.9B | $16.0B | $17.0B | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | $4.2B | $274.0M | $618.0M | $1.9B | $15.8B | $16.6B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $4.4B | $514.0M | $735.0M | $2.0B | $15.7B | $16.3B | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | $4.1B | $331.0M | $908.0M | $1.8B | $15.0B | $15.9B | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | $4.0B | $266.0M | $443.0M | $2.0B | $15.5B | $15.7B | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | $3.8B | $249.0M | $568.0M | $1.7B | $14.3B | $15.5B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $4.0B | $437.0M | $885.0M | $1.7B | $14.0B | $15.4B | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-01-25 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report | 8-K | 2026-10-27 |
| Latest proxy | DEFA14A | 2026-02-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.5% |
| 1 month | +1.7% |
| 3 months | +9.8% |
| Year to date | +17.6% |
| 1 year | +18.6% |
| From 52-week high | -5.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier